No company matches — see all tickers
Only filters 8-Ks. Other selected forms stay visible.
Develops oral anti-inflammatory drugs; plans ruvonoflast Phase 3 in peripheral artery disease, an untested patient population for its lead drug.
No filings match these filters. Show all 8-K events
Request longer coverage
We read every message.
